Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 79.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,383 shares of the biotechnology company’s stock after acquiring an additional 18,827 shares during the quarter. Intech Investment Management LLC’s holdings in Anavex Life Sciences were worth $455,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AVXL. Orion Capital Management LLC lifted its position in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares during the last quarter. PVG Asset Management Corp acquired a new stake in Anavex Life Sciences in the third quarter valued at $74,000. Atria Investments Inc purchased a new stake in Anavex Life Sciences during the 3rd quarter worth about $76,000. BNP Paribas Financial Markets boosted its position in shares of Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 7,421 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $102,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

Anavex Life Sciences stock opened at $9.61 on Tuesday. The company has a market capitalization of $817.47 million, a P/E ratio of -17.47 and a beta of 0.94. Anavex Life Sciences Corp. has a fifty-two week low of $3.25 and a fifty-two week high of $14.44. The stock has a 50-day simple moving average of $9.08 and a 200-day simple moving average of $8.21.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AVXL. D. Boral Capital restated a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, February 12th. HC Wainwright restated a “buy” rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research report on Tuesday, February 18th.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.